Phase II
Roche announced it had temporarily halted recruiting patients to its Phase II MODUL clinical trial for metastatic colorectal cancer after four patient deaths. The patients were receiving Tecentriq (atezolizumab) in combination with Exelixis’ MEK inhibitor Cotellic (cobimetinib).
When a pipe in someone’s house breaks or leaks it can cause a lot of damage to the property if it is not addressed in a timely manner. The same can be said for the pipelines of biopharma companies.
Menlo Therapeutics’ stock dropped 55 percent in premarket trading after announcing its serlopitant failed to meet primary and secondary endpoints in a Phase II clinical trial.
Eidos Therapeutics closed on a $64 million Series B financing round. The funds will be used to advance the company’s product candidate, AG10, into Phase II clinical trials and Phase III trials.
Shares of Conatus Pharmaceuticals dropped 34.3 percent postmarket yesterday after the San Diego-based company announced mixed top-line results for its proof-of-concept trial in liver transplant patients with fibrosis or cirrhosis.
Vivaldi Biosciences announced that its chief scientific officer is delivering a presentation today at the World Vaccine Congress. A new nonclinical trial shows that deltaFLU protected against both distantly drifted and shifted influenza strains, as compared to leading licensed flu vaccines.
Rigel Pharmaceuticals reported a developmental setback for Tavalisse in a mid-stage kidney disease trial. Investors began dumping shares and the stock was down nearly 10 percent.
Investors in La Jolla, Calif.-based MediciNova are celebrating this morning as company shares are up more than 18 percent following the early completion of a mid-stage non-alcoholic steatohepatitis trial.
MediciNova announced that its Phase II clinical trial of ibudilast (MN-166) failed to meet its primary endpoint for methamphetamine dependence.
Analysts look at what else AbbVie has in the pipeline after Rova-T Failure.
PRESS RELEASES